Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies: Next Generation Personal Hematology

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

Inclusion Criteria:

• patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies.
• duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment.
• best response to previous treatment has to be available.
• The patient is able to give written informed consent and wishes to undergo further therapy
• further therapy is medically feasible
• tumor cell-containing samples can be obtained

Exclusion Criteria:

• current participation in another experimental clinical trial
• performance status does not allow participation (ECOG ˃ 1)
• pregnancy, tested at screening
• patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma.
• other malignoma, diagnosed <1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)